For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Sunday Special: 'Modern Love'
'The Interview': Marlon Wayans Lost Nearly 60 Loved Ones. Comedy Saved Him.
The Protesters and the President
Biden Loosens Up on Weed
The New Abortion Fight Before the Supreme Court
The Secret Push That Could Ban TikTok
Trump 2.0: What a Second Trump Presidency Would Bring
Introducing ‘The Interview’: Yair Lapid Says the World Misunderstands Israel
Introducing ‘The Interview’: Anne Hathaway Is Done Trying to Please
Harvey Weinstein Conviction Thrown Out
The Crackdown on Student Protesters
Is $60 Billion Enough to Save Ukraine?
A Salacious Conspiracy or Just 34 Pieces of Paper?
The Evolving Danger of the New Bird Flu
Sunday Special: 'Modern Love'
The Supreme Court Takes Up Homelessness
The Opening Days of Trump’s First Criminal Trial
Are ‘Forever Chemicals’ a Forever Problem?
A.I.’s Original Sin
Iran’s Unprecedented Attack on Israel
Create your
podcast in
minutes
It is Free
Up First
Post Reports
The Journal.
The Ezra Klein Show
Today, Explained